Merger Announced
TELI Pharmaceuticals and Telomir Pharmaceuticals merger
US$47.1m consideration
NASDAQ: TELO
Advisers
Telomir Pharmaceuticals
Target
Not disclosed
Acquirer
- Financial adviser
- Moore
- Fairness opinion
- Moore
- Target
- Telomir Pharmaceuticals
- Target based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Pharma
Similar deals
- Aurinia Pharmaceuticals acquisition of Kezar Life Sciences Mar 2026 · US$51.5m · Biotech
- AnaptysBio outstanding common stock share buy-back Mar 2026 · US$100m · Biotech
- Royalty Pharma acquisition of Neurimmune's royalty interest in AstraZeneca's cliramitug Jul 2026 · US$250m · Pharma
- Amneal Pharmaceuticals acquisition of Kashiv BioSciences Apr 2026 · US$375m · Biotech
- UCB acquisition of Neurona Therapeutics Apr 2026 · US$650m · Biotech